IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immunocore Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.84+0.44 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Immunocore Holdings plc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Revenue from sale of therapies, net | $400.02M | $309.99M | $238.74M | $140.69M | – | 100.0% | +29.0% |
| Collaboration revenue | $0 | $213.00K | $10.69M | $33.67M | – | 0.0% | -100.0% |
| Product revenue, net | – | – | $238.74M | $130.01M | $0 | – | – |
| Pre-Product Revenue [Member] | – | – | $0 | $10.67M | $4.08M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| United States | – | – | $169.79M | $96.89M | $0 | – | – |
| International [Member] | – | – | $1.32M | $1.05M | $0 | – | – |
| Europe | – | – | $67.63M | $42.75M | $4.08M | – | – |
From the segment and revenue-disaggregation notes of Immunocore's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.